Advertisement

Neuroscience Bulletin

, Volume 35, Issue 1, pp 156–166 | Cite as

Pharmacological Modulation of Vagal Nerve Activity in Cardiovascular Diseases

  • Longzhu Liu
  • Ming Zhao
  • Xiaojiang Yu
  • Weijin ZangEmail author
Open Access
Review
  • 384 Downloads

Abstract

Cardiovascular diseases are life-threatening illnesses with high morbidity and mortality. Suppressed vagal (parasympathetic) activity and increased sympathetic activity are involved in these diseases. Currently, pharmacological interventions primarily aim to inhibit over-excitation of sympathetic nerves, while vagal modulation has been largely neglected. Many studies have demonstrated that increased vagal activity reduces cardiovascular risk factors in both animal models and human patients. Therefore, the improvement of vagal activity may be an alternate approach for the treatment of cardiovascular diseases. However, drugs used for vagus nerve activation in cardiovascular diseases are limited in the clinic. In this review, we provide an overview of the potential drug targets for modulating vagal nerve activation, including muscarinic, and β-adrenergic receptors. In addition, vagomimetic drugs (such as choline, acetylcholine, and pyridostigmine) and the mechanism underlying their cardiovascular protective effects are also discussed.

Keywords

Cardiovascular disease Cholinergic drugs Muscarinic receptor α7-nACh receptor Vagus nerve Vagomimetic drugs 

Introduction

The vagus nerve, which is the longest cranial nerve in the human body, innervates the thoracic and abdominal organs, including the autonomic, cardiovascular, respiratory, gastrointestinal, immune, and endocrine systems. The vagus nerve is a key component of the autonomic nervous system (ANS) containing 80% afferent and 20% efferent nerve fibers [1]. The vagal afferent fibers sense a range of stimuli, including pressure, pain, stretch, temperature, chemicals, osmotic pressure, and inflammation. These sensory signals are gathered at the vagal nuclei and are transmitted to multiple brain regions. After being processed in the brain, regulatory signals are transmitted by the vagal efferent fibers. Vagal efferent fibers, which arise from the nucleus ambiguus and the dorsal motor nucleus, are primarily cholinergic, using acetylcholine (ACh) as their major neurotransmitter. Imbalances in the ANS, which are characterized by a reduction in vagal tone accompanied by increased sympathetic activity, are associated with disease progression and negative clinical outcomes, triggering many cardiovascular diseases, such as heart failure [2], arrhythmia [3] and hypertension [4]. Many studies have demonstrated that increased vagal activity reduces cardiovascular risk factors in both animal models and human patients [5, 6, 7, 8]. However, the roles of drugs that activate vagal nerves and vagomimetic drugs in the treatment of cardiovascular disease are still not fully understood.

In the present review, we summarize the recent studies detailing the drugs used in vagal nerve activation for the treatment of cardiovascular disease, as well as putative mechanisms underlying the cardiovascular protective effects of these compounds.

Alteration of Vagal Tone in Cardiovascular Disease

The heart is dominated by both sympathetic and parasympathetic (vagal) nerves. The innervation by sympathetic and vagal nerves is asymmetrical. The right sympathetic and vagal nerves innervating the sinus node and atrium, primarily control the heart rate; the left sympathetic and vagal nerves innervating the atrioventricular junction and the left ventricle, primarily control myocardial contractility and cardiac output [9]. The vagus nerve plays a vital role in maintaining normal cardiovascular function. Under physiological conditions, the sympathetic and parasympathetic (vagal) activities modulating cardiac function undergo a reciprocal regulation, leading to sympathovagal balance [10]. The sympathetic neurotransmitter catecholamine is released, which increases the heart rate and myocardial contractility [11]. Simultaneously, the vagal nerve releases ACh to reduce the conduction of pacemaker cells in the sinus node, thereby lowering the heart rate and the myocardial contractility [12]. Under pathological conditions, autonomic imbalance and increased cardiac sympathetic nerve activity lead to an increased heart rate, increased myocardial contractility, and increased myocardial oxygen consumption. Meanwhile, decreased vagal nerve discharge and a decrease in the amount of ACh released into the synaptic cleft, lead to the loss of the ability of the vagal nerve to reduce the heart rate and decrease myocardial contractility. Ultimately, this loss results in cardiac overload and enhanced cardiovascular damage [4]. Thus, the restoration or enhancement of vagal nerve activity may be a promising therapy for cardiovascular disease.

The activation of vagal nerves occurs at multiple levels, including the afferent, central, and efferent components and all related effectors. Our primary concern is the relationship between activation of the vagal efferent component and cardiovascular disease. Vagal efferents can be activated during the following processes: (1) an increase in neuronal discharge and ACh release by activation of the central axis and direct vagal nerve stimulation; (2) the administration of cholinergic drugs or the indirect increase in ACh levels by administration of cholinesterase inhibitors; and (3) an increase in ACh bioavailability by activation of the ACh-associated receptors (M receptors and the N receptor) and downstream pathways.

Although many methods can be used to study vagal activity in experiments, only heart rate variability (HRV) and baroreflex sensitivity (BRS) are commonly used in the clinic [13]. HRV and BRS are important markers that are typically used to indirectly assess vagal activity [14, 15, 16, 17, 18, 19, 20, 21]. BRS is primarily regarded as a measure of vagal reflex activity and is expressed in milliseconds of increase in the RR interval consequent to an increase of 1 mmHg in blood pressure [22]. HRV is the variation over time of the period between consecutive heartbeats [23]. Other methods, such as the ACh level in the blood measured by microdialysis [6], cardiac automatic nerves and cholinergic nerve distribution by immunohistochemistry [24], autonomic tone and intrinsic heart rate by administration of atropine and propranolol [25, 26] or neuronal/vagal discharge measured by a biological signal analytical system [27], can also be used to evaluate vagal activity in experiments (Fig. 1).
Fig. 1

Methods and indices used to evaluate vagal activity in cardiovascular disease. Vagus activity can be evaluated by (I) measurement of the vagal discharge (image adapted from Lu Y et al. [27]); (II) autonomic tone and intrinsic heart rate; (III) HRV and BRS; (IV) cardiac autonomic nerves and cholinergic nerve distribution; and (V) detection of the release of ACh into the circulation (image adapted from Zhao M et al. [6]). ACh, acetylcholine; BRS, baroreflex sensitivity; HPLC, high performance liquid chromatography; HRV, heart rate variability; PSYM, parasympathetic; SYM, sympathetic.

Decreased Vagal Tone is Associated with Increased Mortality in Heart Failure

Heart failure (HF) is a leading cause of morbidity and mortality. The ANS plays an important role in regulating pathological cardiac remodeling in HF. An imbalance in the ANS is a predictor for a negative prognosis in patients with HF. It has been demonstrated that decreased vagal tone is associated with an increase in mortality for HF [28]. A recent report indicates that the neurotransmitter response of the cardiac vagal neurons in the brain stem is altered [29]. The sympathovagal imbalance often results in left ventricular dysfunction during the early stages of HF [30]. Decreased ventricular epicardial vagal nerve density has also been reported to potentially contribute to impaired cardiac vagal control in rats with HF [31]. For the treatment of HF, vagus nerve stimulation (VNS) has been shown to be beneficial for improving the autonomic balance in HF by enhancing vagal tone [32]. A recent report has also shown that short-term intravenous VNS markedly reduces infarct size and prevents subsequent HF. The bradycardic effect may play an important role in the beneficial effect of VNS [33].

Arrhythmia with Reduced Vagal Tone after Myocardial Infarction

Many studies have indicated that the ANS plays a pivotal role in the development of arrhythmias [34, 35, 36]. Electrical wave-break-induced re-entry can cause the onset of arrhythmia. Wave-break is primarily affected by two factors. Anatomical factors, such as scars and fibrosis, affect wave-break and lead to tissue heterogeneity and electrical remodeling. Changes in membrane voltage and intracellular Ca2+ levels also affect wave-break. Arrhythmia with reduced vagal tone after myocardial infarction is a life-threatening risk factor [13]. We have reported that cholinergic nerves and M2 receptors are located in both rat atria and ventricles [37]. Inagaki et al. have found that VNS reduces the rate of ventricular fibrillation from 62% to 7% in cats [38]. Over the years, VNS has been shown not only to slow down the sinus rate but also to display many beneficial effects that protect the heart against ventricular arrhythmias, including decreased heart rate, reduced atrioventricular conduction, and reduced atrial contraction [39]. Vagal modulation plays a significant role in the initiation and development of arrhythmias, and novel vagomimetic drug discovery may hold the key to treatment.

Reduced Vagal Activity Contributes to Hypertensive Organ Damage

The ANS plays a critical role in maintaining cardiovascular homeostasis during hypertension. Vagal nerve fibers can modulate local and systemic inflammatory responses, known as the ‘cholinergic anti-inflammatory pathway’ [40]. Both a decrease in ACh release and dysfunction of the α7 nicotinic ACh receptor contribute to hypertensive organ damage. Recently, chronic VNS has been reported to prevent hypertension-induced endothelial dysfunction and aortic stiffening in spontaneously hypertensive rats (SHRs) [41]. Our group also demonstrated that an increase in the expression of TLR4 and pro-inflammatory cytokines may be correlated with suppressed vagal activity in SHRs [16]. Therefore, increasing vagal activity may be an interesting alternative approach for antihypertensive therapy.

Abnormal ANS activity is correlated with many other cardiovascular diseases, such as myocardial infarction [42], ischemia/reperfusion injury [43], and atherosclerosis [44]. In summary, the vagal nerve plays an important role in many cardiovascular diseases, and further investigation is required to find therapies for restoring impaired vagal nerve function to improve clinical outcomes and prognoses.

Potential Targets for Vagal Nerve Activation in Cardiovascular Disease

Muscarinic Receptors and Cardiovascular Diseases

Cholinergic receptors are conventionally divided into two types of ACh receptors (AChRs), namely, the muscarinic and nicotinic receptors. The muscarinic ACh receptor (mAChR) is a member of a sub-family of G protein-coupled receptors that includes the M1–M5 subtypes [45]. These mAChRs exist in many tissues and cells, acting under the control of parasympathetic innervation. Among these mAChRs, the M2 and M3 receptor subtypes are important in the cardiovascular system. Previous studies have shown that the M2 receptor is primarily distributed in myocardial cells [46]. Our studies have also shown that ACh inhibits tumor necrosis factor alpha production by downregulating p38 mitogen-activated protein kinase (MAPK) and JNK phosphorylation; this is mediated by the M2 receptor, and M2 antagonists or the knockdown of M2 receptor expression by siRNA abolishes the effects of ACh-induced protection in cardiomyocytes [47, 48]. Recent studies have found that the M3 receptor subtype is also distributed in myocardial cells [49], and plays a protective role in cardiovascular disease [50]. Some studies have reported that M3 receptor activation reduces angiotensin II-induced cardiac hypertrophy, corrects cardiac hemodynamic dysfunction, inhibits myocardial cell apoptosis, and reduces myocardial injury [51]. A recent study indicated that activation of the M3 receptor by VNS improves mitochondrial dynamics and mitochondrial function in isoproterenol-induced myocardial ischemia [52]. The pharmacological activation of M3 receptors also has a cardioprotective effect in ischemia-induced ischemia/reperfusion (I/R) injury [7]. Furthermore, the overexpression of M3 receptors decreases the incidence of arrhythmias in a mouse model of myocardial I/R injury [53].

Nicotinic Acetylcholine Receptors and Cardiovascular Diseases

Nicotinic ACh receptors (nAchRs) are ion channels formed by five subunits delimiting a central aqueous pore. nAchRs have been identified in many cell types, including vascular smooth muscle cells [54] and endothelial cells [55]. nAchRs have been suggested to be involved in the cardioprotection conferred by vagal nerve stimulation [14]. In particular, the primary function of the α7nAchR subtype in mediating this inflammatory response is now well-accepted [56]. ACh binds to the α7nAchR, which inhibits the transcriptional activity of p38 MAPK and nuclear factor-kappa B [57]. Furthermore, α7nAchR activation can also recruit Janus kinase 2 (Jak2) to form a heterodimeric complex, initiating an intracellular transduction response mediated by signal transducer and activator of transcription 3 (STAT3) [58]. Vagal stimulation protects against myocardial I/R-induced remote vascular dysfunction through the cholinergic anti-inflammatory pathway, which is dependent upon α7nACh receptors [6]. Previous studies have also shown that α7nACh receptors block inflammasome complex activation by suppressing mitochondrial DNA release [59]. Therefore, the pharmacological activation of α7nAchR, by improving vagal activity, characterizes an alternative approach for treating cardiovascular disease.

β2 Adrenergic Receptors and Cardiovascular Disease

Adrenergic receptors (ARs) are a large family of seven-transmembrane domain receptors responsive to catecholamines. ACh released by the vagus nerve in the celiac mesenteric ganglia activates the splenic nerve through postsynaptic α7nAchRs [60]. Then, noradrenaline released from splenic nerve terminals promotes β2AR activation in T cells in the spleen [61]. The β2AR-activated T cells then produce ACh, which activates α7nAchRs on cytokine-producing macrophages, thus inhibiting the release of cytokines from the spleen [62]. These studies have indicated that β2AR-activated T cells in the spleen are critical for the anti-inflammatory action of the vagus nerve [63], and β2ARs represent a potential pharmacological target for vagal activation in cardiovascular disease.

Drugs for Cardioprotection by Vagal Nerve Activation

Modulation of the vagal nerve activity is theoretically a promising therapy for cardiovascular disease. Current, major, non-drug-activated vagal nerve activation approaches include direct vagal stimulation through surgically implanted stimulators [64], and indirect renal sympathectomy [65], aerobic exercise, and yoga [66]. At present, VNS has been clinically applied in patients with drug-resistant epilepsy, depression, and heart failure. VNS has also been found to have a protective effect against myocardial infarction-induced arrhythmias, inhibit the abnormal ventricular electrophysiological changes that can be induced by sympathetic over-activation, and reduce the incidence of heart fibrillation [64].

Although there is already much evidence that direct VNS can effectively improve the occurrence and development of cardiovascular disease [52, 64], due to surgical trauma, poor patient compliance, and an inadequate response in patients with cardiac insufficiency, its widespread application in the clinic has been limited. Therefore, activation of the vagus nerve by pharmacological tools may be another option for patients with cardiovascular disease as an alternative to direct VNS. The primary drug targets used for vagal nerve activation in cardiovascular diseases have included: (1) vagomimetic agents that directly increase the levels of synaptic ACh to activate muscarinic and nicotinic receptors; (2) cholinesterase inhibitors that indirectly decrease the degradation of ACh; and (3) adenosine, statins, beta-receptor blockers and angiotensin-converting-enzyme inhibitors (ACEIs), which also indirectly activate vagal tone; however, the underlying mechanisms through which these drugs stimulate vagal activation still require further investigation (Fig. 2).
Fig. 2

Schematic of the drug targets for vagal nerve activation. A The vagal transmitter ACh is synthesized in vivo by the catalysis of choline and acetyl-CoA by choline acetyltransferase, thus directly increasing the levels of synaptic ACh [67]. B Cholinesterase inhibitors increase the levels of synaptic ACh by decreasing its degradation, and thus directly increasing vagal tone [68]. C Adenosine [69], statins [70], beta-receptor blockers [71], and ACEIs [72] indirectly activate vagal tone by acting on the related receptors. Acetyl-CoA, Acetyl-coenzyme A; AChE, acetylcholine esterase; ACEIs, angiotensin-converting-enzyme inhibitors; ACh, acetylcholine.

Cholinergic Drugs Used in the Treatment of Cardiovascular Diseases

Choline

The essential nutrient choline participates in various biological processes. It is a component of two biologically important molecules, phosphatidylcholine and ACh. Choline has been used in the clinical treatment of steatohepatitis [73]. Accumulating evidence has demonstrated that choline also has multiple protective effects against various cardiovascular diseases, including myocardial infarction [42], arrhythmias [74], cardiac hypertrophy [75, 76], and I/R injury [77]. Choline has also been demonstrated to have a protective effect against vascular damage in rats after I/R through the inhibition of the reactive oxygen species (ROS)-mediated Ca2+/calmodulin-dependent protein kinase II (CaMKII) pathway and the regulation of Ca2+cycling proteins. These protective effects may be attributed to activation of the M3 receptor [7]. Recently, our group demonstrated that choline slows the progress of hypertension and ameliorates cardiac, renal, and vascular damage in SHRs. These protective effects may be related to the improvement in vagal activity and the reduction in inflammatory cytokines found in SHRs [16]. These studies indicate that choline may be a promising therapeutic agent for the alleviation of cardiovascular damage in cardiovascular disease, although the mechanisms underlying its cardiovascular protective effects require further investigation.

Acetylcholine

ACh is the endogenous agonist for the two primary types of cholinoceptor, the muscarinic and nicotinic receptors and they will likely become novel targets for drug development [78]. In vivo microdialysis studies have demonstrated that vagal stimulation increases the ACh concentration in the mesenteric circulation, suggesting that the ACh released from the vagus nerve is transported into the mesenteric circulation and has effects on endothelial cells and vascular smooth muscle cells [6]. Studies in our laboratory have demonstrated that ACh prevents angiotensin II-induced cardiomyocyte injury through down-regulation of the angiotensin II type 1 receptor and inhibition of ROS-mediated p38 MAPK activation, as well as regulation of Bcl-2, Bax, and caspase-3 expression [48, 79, 80, 81]. Recently, we demonstrated that ACh markedly suppresses the mitochondrial unfolded protein response and endoplasmic reticulum stress, which alleviate I/R injury [82, 83]. ACh may also modulate the abnormal inter-organelle crosstalk in cardiovascular diseases. Our studies indicated that ACh attenuates intracellular Ca2+ overload by inhibiting the formation of the VDAC1/Grp75/IP3R1 complex and the NCX1-TRPC3-IP3R1 complex in mitochondria-endoplasmic reticulum and endoplasmic reticulum-plasma membrane connection sites in human umbilical vein endothelial cells, indicating that the inhibition of inter-organelle crosstalk may be a mechanism for vagal protective effects in cardiovascular disease [84, 85]. Currently, ACh is primarily used as a pharmaceutical tool due to the multiple effects that it has throughout the body.

Acetylcholinesterase Inhibitors for the Treatment of Cardiovascular Disease

Pyridostigmine

There are two types of cholinesterase inhibitors: reversible anticholinesterase and irreversible cholinesterase inhibitors. Irreversible cholinesterase inhibitors are used as organic pesticides and are highly toxic, while reversible anticholinesterases have relatively lower toxicity. Peripheral reversible acetylcholinesterase inhibitors such as pyridostigmine bromide (PYR) have been used for the clinical treatment of myasthenia gravis and chronic heart failure [86, 87]. In addition, the development of new delivery methods (e.g., liposomes and nanoparticles) may reduce the side-effects of PYR [88, 89]. Evidence has shown that long-term treatment with PYR increases cardiac vagal tone, reduces sympathetic tone, and attenuates cardiac remodeling and left ventricular dysfunction during the progress of HF in mice [90]. More recent studies have demonstrated important roles for PYR in preserving autonomic balance [91, 92]. Our studies have also suggested that PYR restores baroreflex sensitivity, improves HRV, inhibits renin-angiotensin-system (RAS) activation and suppresses angiotensin II-induced cardiac fibroblast activation, thus ameliorating cardiac remodeling and improving peripheral vascular endothelial function in rats with myocardial infarctions or abdominal aortic constriction [17, 27, 93, 94]. These data support the notion that the enhancement of vagal tone by PYR is beneficial during cardiovascular disease. Seven days of PYR treatment has been demonstrated to improve intrinsic heart rate and autonomic tone, while reducing the area of myocardial infarction [95]. Yu et al. [96] have demonstrated that PYR treatment increases capillary density after myocardial infarction in rats. In addition, Durand et al. [97] have concluded that the immediate administration of this drug after myocardial infarction is an important pharmacological intervention to protect against potentially negative changes in cardiac autonomic imbalance. A recent report also indicated that PYR associated with exercise training benefits cardiovascular autonomic modulation and reduces inflammatory responses in infarcted rats [98]. Chronic treatment with PYR or donepezil increases cardiac vagal tone, reduces cardiomyocyte diameter, collagen density, and inflammatory cytokine levels in the plasma of SHRs [99]. Thus, the administration of acetylcholinesterase inhibitors may pharmacologically mimic activation of the cholinergic system, and contribute to cytokine production and the amelioration of myocardial infarction. The most recent study also demonstrated that the administration of PYR for 12 weeks ameliorates the cardiomyopathy induced by a high-fat diet in Sprague-Dawley rats, which is accompanied by improved vagal activity, reduced cardiac lipid accumulation, and the facilitated browning of white adipose tissue while activating brown adipose tissue [100]. However, studies are still necessary to better understand the pleiotropic effects of PYR on cardiovascular protection.

Other Drugs for Cardiovascular Protection (Adenosine, Statins, β-Receptor Blockers, and ACEIs)

Adenosine

Studies have demonstrated a functional link between adenosine and the vagal nerve activity [69]. Our study also demonstrated a possible functional interaction between muscarinic M2 receptors and α1 adenosine receptors in the I/R myocardium, and nitric oxide synthase may be the link between these two types of receptors [101]. Interestingly, adenosine has beneficial effects on M2 receptors, thus playing a role in the improvement of cardiac function. These results have demonstrated a possible new mechanism for the cardioprotection provided by adenosine. The precursor of adenosine (adenine sulfate) has also been suggested to have cardioprotective effects by increasing the expression of M2 receptors and cholinergic nerve density [102]. A recent study suggested that the inhibitory effects of VNS on HR and BP are partly mediated by endogenous adenosine release [103].

Statins

Statin, the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor, is used routinely in coronary artery disease for its lipid-lowering effect. Evidence has indicated that the pleiotropic effects of statins may be involved in improving endothelial function, inhibiting inflammation and oxidative stress, attenuating myocardial remodeling, and stabilizing atherosclerotic plaques [104]. Our previous study demonstrated that atorvastatin enhances serum ACh levels and baroreflex sensitivity in I/R injury in rats [70]. In a human study, atorvastatin also had a beneficial impact on vagal activity, as measured by improvements in HRV, and might reduce the risk for arrhythmias in HF patients [105]. A recent study suggested that statins might reduce arrhythmias and improve HRV in healthy persons after 48 h of sleep deprivation [106]. The ejection fraction of HF patients without ischemic heart disease is preserved by stains [107]. However, the details of the underlying mechanisms of the effects of statins on cholinergic systems are still not fully clarified.

β-Adrenoceptor Blockers

β-Blockers improve the prognoses of patients with HF. However, their protective effect is not fully dependent on the direct blockade of sympathetic activity. The sympathetic–parasympathetic interaction plays an important role in many cardiovascular diseases. The afferent sympathetic excitation results in activation of sympathetic efferent activity, together with the inhibition of vagal activity. These phenomena are antagonized by β-blockers [22]. β-ARs include three subtypes (β1, β2, and β3) [108]. Among them, β1 is primarily expressed in the heart. The cardiovascular protective effects exerted by β-blockers are due primarily to inhibition of the β1 receptor [109]. A previous study showed that carvedilol (an α- and β-blocker) increases the expression of M2 receptors in myocardium injured by adriamycin, implying that the up-regulation of these muscarinic receptors may be partly responsible for the protective effects of carvedilol in HF [71]. It has also been reported that long-term treatment with carvedilol restores autonomic tone and responsiveness in patients with moderate HF [110]. Vagal activation induced by metoprolol, another β-blocker, prevents ventricular fibrillation in mice with dilated cardiomyopathy [111].

Angiotensin-Converting-Enzyme Inhibitors

Ramipril, an ACEI, increases HRV and cardiac function in patients with renal failure [112]. A recent study has also demonstrated that enalapril, combined with aerobic physical training, increases vagal tone [72]. In addition, delapril improves the sympatho-vagal balance and reduces atrioventricular blocks and ventricular arrhythmia [113]. Therefore, ACEIs might be a promising type of vagomimetic drug for the treatment of cardiovascular disease; however, clarifying the potential mechanism requires more studies.

Conclusion

In this review, we have provided an overview of recent studies on the drug targets and vagomimetic drugs for vagus nerve activation in the treatment of cardiovascular disease (Table 1). This review shows that there has been a surge of data to suggest that decreased vagal activity is closely associated with the development of cardiovascular diseases and poor clinical outcomes. Targeting the vagus may be a promising therapeutic approach for the treatment of cardiovascular disease. Some vagomimetic drugs have been developed for the activation of vagal activity in cardiovascular diseases. The cardiovascular protective effects of these vagomimetic drugs may be predominantly correlated with a decrease in inflammation, the prevention of Ca2+ overload and the inhibition of RAS by improving vagal activity. The drugs discussed in this review all target vagal activation in cardiovascular diseases. Further study of these drug targets may help us to understand the mechanisms underlying vagal activation in these diseases.
Table 1

Drugs used in vagal nerve activation and potential mechanisms.

Classification

Drug

Mechanism

References

Cholinergic drugs

Choline

Increase of ACh levels

Liu, et al. 2017 [16]

α7nAChR agonist

Lu, et al. 2015 [7]

M3 agonist

Zhao, et al. 2010 [77]

Inhibition of CaMKII and calcineurin

Wang, et al. 2012 [75]

Inhibition of ROS

 

ACh

Down-regulation of AT1 receptor

Liu, et al. 2011 [79]

Inhibition of ER stress

Bi, et al. 2015 [82]

Inhibition of UPRmt

Xu, et al. 2016 [83]

Inhibition of Ca2+ overload

He, et al. 2015 [84]

M2/M3 agonist

Zhao, et al. 2017 [85]

AChE inhibitors

Pyridostigmine

AChE inhibition

Lataro, et al. 2015 [90]

Donepezil

Anti-inflammation

Durand, et al. 2014 [91]

Gavioli, et al. 2014 [92]

Lu, et al. 2017 [27]

Lu, et al. 2018 [100]

Nucleoside

Adenosine

Enhancement of cholinergic nerve density. Increase of M2 receptor expression

da Silva, et al. 2012 [69]

Sun, et al. 2011[101]

Jammes, et al. 2015 [103]

Statins

Simvastatin

Improvement of HRV

Millar, et al. 2014[104]

Atorvastatin

Decrease of QT variability

Bi, et al. 2013 [70]

β-blockers

Carvedilol

Increase of M2 receptor expression

Xu, et al. 2006 [71]

Metoprolol

improvement of HRV

Zhan, et al. 2009 [111]

ACEIs

Ramipril

Increase of HRV, cardiac function

Maida, et al. 2016 [72]

Enalapril

Inhibition of RAS activation

Thireau, et al. 2015 [113]

Delapril

Inhibition of Ca2+ overload

ACh, acetylcholine; AChE, acetylcholine esterase; CaMKII, Ca2+ /calmodulin-dependent protein kinase II; ER, endoplasmic reticulum; HRV, heart rate variability; RAS, renin-angiotensin-system; ROS, reactive oxygen species; UPRmt, mitochondrial unfolded protein response.

Notes

Acknowledgements

This review was supported by grants from the National Natural Science Foundation of China (81770293 and 81473203).

Compliance with ethical standard

Conflict of interest

The authors confirm no conflict of interest.

References

  1. 1.
    Bonaz B, Sinniger V, Pellissier S. Anti-inflammatory properties of the vagus nerve: potential therapeutic implications of vagus nerve stimulation. J Physiol 2016, 594: 5781–5790.Google Scholar
  2. 2.
    Abboud FM, Benson CJ. ASICs and cardiovascular homeostasis. Neuropharmacology 2015, 94: 87–98.Google Scholar
  3. 3.
    Arslan M, Yesilcan N, Aydin D, Yüksel R, Dane S. Wet cupping therapy restores sympathovagal imbalances in cardiac rhythm. J Altern Complement Med 2014, 20: 318–321.Google Scholar
  4. 4.
    Mancia G, Grassi G. The autonomic nervous system and hypertension. Circ Res 2014, 114: 1804–1814.Google Scholar
  5. 5.
    La Rovere MT, Christensen JH. The autonomic nervous systemand cardiovascular disease: role of n-3 PUFAs. Vascul Pharmacol 2015, 71: 1–10.Google Scholar
  6. 6.
    Zhao M, He X, Bi XY, Yu XJ, Gil Wier W, Zang WJ. Vagal stimulation triggers peripheral vascular protection through the cholinergic anti-inflammatory pathway in a rat model of myocardial ischemia/reperfusion. Basic Res Cardiol 2013, 108: 345.Google Scholar
  7. 7.
    Lu XZ, Bi XY, He X, Zhao M, Xu M, Yu XJ, et al. Activation of M3 cholinoceptors attenuates vascular injury after ischaemia/reperfusion by inhibiting the Ca2+/calmodulin-dependent protein kinase II pathway. Br J Pharmacol 2015, 172: 5619–5633.Google Scholar
  8. 8.
    Petkovich BW, Vega J, Thomas S. Vagal modulation of hypertension. Curr Hypertens Rep 2015, 17: 532.Google Scholar
  9. 9.
    Masaki I, Keiichi F. Cardiac innervation and sudden cardiac death. Circ Res 2015, 116: 2005–2019.Google Scholar
  10. 10.
    Brandenberger G, Viola AU. Autonomic Nervous System Activity during Sleep in Humans. Springer, US: 2006.Google Scholar
  11. 11.
    Zhang DY, Anderson AS. The sympathetic nervous system and heart failure. Cardiol Clin 2014, 32: 33–45.Google Scholar
  12. 12.
    Dyavanapalli J, Dergacheva O, Wang X, Mendelowitz D. Parasympathetic vagal control of cardiac function. Curr Hypertens Rep 2016, 18: 22.Google Scholar
  13. 13.
    Pitzalis MV. Baroreflex sensitivity and heart rate variability in the identification of patients at risk for life-threatening arrhythmias: implications for clinical trials. Circulation 2001, 103: 2072–2077.Google Scholar
  14. 14.
    Klippel BF, Duemke LB, Leal MA, Friques AG, Dantas EM, Dalvi RF, et al. Effects of Kefir on the cardiac autonomic tones and baroreflex sensitivity in spontaneously hypertensive rats. Front Physiol 2016, 7: 211.Google Scholar
  15. 15.
    Gao J, Zucker IH, Gao L. Activation of central angiotensin type 2 receptors by compound 21 improves arterial baroreflex sensitivity in rats with heart failure. Am J Hypertens 2014, 27: 1248–1256.Google Scholar
  16. 16.
    Liu L, Lu Y, Bi X, Xu M, Yu X, Xue R, et al. Choline ameliorates cardiovascular damage by improving vagal activity and inhibiting the inflammatory response in spontaneously hypertensive rats. Sci Rep 2017, 7: 42553.Google Scholar
  17. 17.
    Qin F, Lu Y, He X, Zhao M, Bi X, Yu X, et al. Pyridostigmine prevents peripheral vascular endothelial dysfunction in rats with myocardial infarction. Clin Exp Pharmacol Physiol 2014, 41: 202–209.Google Scholar
  18. 18.
    Rudas L, Crossman AA, Morillo CA, Halliwill JR, Tahvanainen KU, Kuusela TA, et al. Human sympathetic and vagal baroreflex responses to sequential nitroprusside and phenylephrine. Am J Physiol 1999, 276: 1691–1698.Google Scholar
  19. 19.
    Jarczok MN, Koenig J, Shively CA, Thayer JF. Behavioral depression is associated with increased vagally mediated heart rate variability in adult female cynomolgus monkeys (Macaca fascicularis). Int J Psychophysiol 2018, 131: 139–143.Google Scholar
  20. 20.
    Liu H, Yang Z, Meng F, Huang L, Qu W, Hao H, et al. Chronic vagus nerve stimulation reverses heart rhythm complexity in patients with drug-resistant epilepsy: An assessment with multiscale entropy analysis. Epilepsy Behav 2018, 83: 168–174.Google Scholar
  21. 21.
    Setty AB, Vaughn BV, Quint SR, Robertson KR, Messenheimer JA. Heart period variability during vagal nerve stimulation. Seizure 1998, 7: 213–217.Google Scholar
  22. 22.
    Schwartz PJ, De Ferrari GM. Sympathetic–parasympathetic interaction in health and disease: abnormalities and relevance in heart failure. Heart Fail Rev 2010, 16: 101–107.Google Scholar
  23. 23.
    Taralov ZZ, Terziyski KV, Kostianev SS. Heart rate variability as a method for assessment of the autonomic nervous system and the adaptations to different physiological and pathological conditions. Folia Med (Plovdiv) 2015, 57: 173–180.Google Scholar
  24. 24.
    Wang YH, Hu H, Wang SP, Tian ZJ, Zhang QJ, Li QX, et al. Exercise benefits cardiovascular health in hyperlipidemia rats correlating with changes of the cardiac vagus nerve. Eur J Appl Physiol 2010, 108: 459–468.Google Scholar
  25. 25.
    Machado BH, Brody MJ. Contribution of neurogenic mechanisms to control of intrinsic heart rate. Am J Physiol 1989, 256: 231–235.Google Scholar
  26. 26.
    Kalume F, Westenbroek RE, Cheah CS, Yu FH, Oakley JC, Scheuer T, et al. Sudden unexpected death in a mouse model of Dravet syndrome. J Clin Investig 2013, 123: 1798–1808.Google Scholar
  27. 27.
    Lu Y, Zhao M, Liu JJ, He X, Yu XJ, Liu LZ, et al. Long-term administration of pyridostigmine attenuates pressure overload-induced cardiac hypertrophy by inhibiting calcineurin signalling. J Cell Mol Med 2017, 21: 2106–2116.Google Scholar
  28. 28.
    Bhardwaj A, Dunlap ME. Autonomic dysregulation as a therapeutic target for acute HF. Curr Treat Options Cardiovasc Med 2015, 17: 1–12.Google Scholar
  29. 29.
    Cauley E, Wang X, Dyavanapalli J, Sun K, Garrott K, Kuzmiak-Glancy S, et al. Neurotransmission to parasympathetic cardiac vagal neurons in the brain stem is altered with left ventricular hypertrophy-induced heart failure. Am J Physiol Heart Circ Physiol 2015, 309: H1281–1287.Google Scholar
  30. 30.
    Wang N, Hung CL, Shin SH, Claggett B, Skali H, Thune JJ, et al. Regional cardiac dysfunction and outcome in patients with left ventricular dysfunction, heart failure, or both after myocardial infarction. Eur Heart J 2016, 37: 466–472.Google Scholar
  31. 31.
    Delfiner MS, Siano J, Li Y, Dedkov EI, Zhang Y. Reduced epicardial vagal nerve density and impaired vagal control in a rat myocardial infarction-heart failure model. Cardiovasc Pathol 2016, 26: 21–29.Google Scholar
  32. 32.
    Zhang Y, Popović ZB, Bibevski S, Fakhry I, Sica DA, Wagoner DRV, et al. Chronic vagus nerve stimulation improves autonomic control and attenuates systemic inflammation and heart failure progression in a canine high-rate pacing model. Circ Heart Fail 2009, 2: 692–699.Google Scholar
  33. 33.
    Arimura T, Saku K, Kakino T, Nishikawa T, Tohyama T, Sakamoto T, et al. Intravenous electrical vagal nerve stimulation prior to coronary reperfusion in a canine ischemia-reperfusion model markedly reduces infarct size and prevents subsequent heart failure. Int J Cardiol 2017, 227: 704–710.Google Scholar
  34. 34.
    Shen MJ, Zipes DP. Role of the autonomic nervous system in modulating cardiac arrhythmias. Circ Res 2014, 114: 1004–1021.Google Scholar
  35. 35.
    Nederend I, Ejc DG, Ljm K, Jjm W, Blom NA, Adj TH. Cardiac autonomic nervous system activity and cardiac function in children after coarctation repair. Ann Thorac Surg 2018, 105: 1803–1808.Google Scholar
  36. 36.
    Winter J, Tipton M, Shattock MJ. Autonomic conflict exacerbates long QT associated ventricular arrhythmia. J Mol Cell Cardiol 2018, 116: 145–154.Google Scholar
  37. 37.
    Xu XL, Zang WJ, Kang XQ, Li M, Yu XJ, Chen LN, et al. Comparison of distribution of cholinergic nerves and M2 receptors between rat atria and ventricles. Nan Fang Yi Ke Da Xue Xue Bao 2006, 26: 1096–1100.Google Scholar
  38. 38.
    Inagaki M, Kawada T, Lie M, Zheng C, Sunagawa K, Sugimachi M. Intravascular parasympathetic cardiac nerve stimulation prevents ventricular arrhythmias during acute myocardial ischemia. Conf Proc IEEE Eng Med Biol Soc 2005, 7: 7076–7079.Google Scholar
  39. 39.
    Ng GA. Neuro-cardiac interaction in malignant ventricular arrhythmia and sudden cardiac death. Auton Neurosci 2016, 199: 66–79.Google Scholar
  40. 40.
    Carnevale D, Perrotta M, Pallante F, Fardella V, Iacobucci R, Fardella S, et al. A cholinergic-sympathetic pathway primes immunity in hypertension and mediates brain-to-spleen communication. Nat Commun 2016, 7: 13035.Google Scholar
  41. 41.
    Chapleau MW, Rotella DL, Reho JJ, Rahmouni K, Stauss HM. Chronic vagal nerve stimulation prevents high-salt diet-induced endothelial dysfunction and aortic stiffening in stroke-prone spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 2016, 311: H276–285.Google Scholar
  42. 42.
    Wang S, Han HM, Jiang YN, Wang C, Song HX, Pan ZY, et al. Activation of cardiac M3 muscarinic acetylcholine receptors has cardioprotective effects against ischaemia-induced arrhythmias. Clin Exp Pharmacol Physiol 2012, 39: 343–349.Google Scholar
  43. 43.
    Sun L, Zhao M, Yang Y, Xue RQ, Yu XJ, Liu JK, et al. Acetylcholine attenuates hypoxia/reoxygenation injury by inducing mitophagy through PINK1/Parkin signal pathway in H9c2 cells. J Cell Physiol 2016, 231: 1171–1181.Google Scholar
  44. 44.
    Kadoya M, Koyama H, Kurajoh M, Kanzaki A, Kakutanihatayama M, Okazaki H, et al. Sleep, cardiac autonomic function, and carotid atherosclerosis in patients with cardiovascular risks: HSCAA study. Atherosclerosis 2015, 238: 409–414.Google Scholar
  45. 45.
    Harvey RD. Muscarinic Receptor Agonists and Antagonists: Effects on Cardiovascular Function. Handbook of Experimental Pharmacology 2012, 208: 299–316.Google Scholar
  46. 46.
    Krejcí A, Tucek S. Quantitation of mRNAs for M(1) to M(5) subtypes of muscarinic receptors in rat heart and brain cortex. Mol Pharmacol 2002, 61: 1267–1272.Google Scholar
  47. 47.
    Li DL, Liu JJ, Liu BH, Hu H, Sun L, Miao Y, et al. Acetylcholine inhibits hypoxia-induced tumor necrosis factor-α production via regulation of MAPKs phosphorylation in cardiomyocytes. J Cell Physiol 2011, 226: 1052–1059.Google Scholar
  48. 48.
    Miao Y, Zhou J, Zhao M, Liu J, Sun L, Yu X, et al. Acetylcholine attenuates hypoxia/ reoxygenation-induced mitochondrial and cytosolic ROS formation in H9c2 cells via M2 acetylcholine receptor. Cell Physiol Biochem 2013, 31: 189–198.Google Scholar
  49. 49.
    Patanè S. M3 muscarinic acetylcholine receptor in cardiology and oncology. Int J Cardiol 2014, 177: 646–649.Google Scholar
  50. 50.
    Hang PZ, Zhao J, Qi JC, Wang Y, Wu JW, Du ZM. Novel insights into the pervasive role of M3 muscarinic receptor in cardiac diseases. Curr Drug Targets 2013, 14: 372–377.Google Scholar
  51. 51.
    Liu Y, Wang S, Wang C, Song H, Han H, Hang P, et al. Upregulation of M3 muscarinic receptor inhibits cardiac hypertrophy induced by angiotensin II. J Transl Med 2013, 11: 209.Google Scholar
  52. 52.
    Xue RQ, Sun L, Yu XJ, Li DL, Zang WJ. Vagal nerve stimulation improves mitochondrial dynamics via an M3 receptor/CaMKKβ/AMPK pathway in isoproterenol-induced myocardial ischaemia. J Cell Mol Med 2017, 21: 58–71.Google Scholar
  53. 53.
    Liu Y, Sun L, Pan Z, Bai Y, Wang N, Zhao J, et al. Overexpression of M3 muscarinic receptor is a novel strategy for preventing sudden cardiac death in transgenic mice. Mol Med 2011, 17: 1179–1187.Google Scholar
  54. 54.
    Oz M, Lorke DE, Yang KH, Petroianu G. On the interaction of β-amyloid peptides and α7-nicotinic acetylcholine receptors in Alzheimer’s disease. Curr Alzheimer Res 2013, 10: 618–630.Google Scholar
  55. 55.
    Li DJ, Huang F, Ni M, Fu H, Zhang LS, Shen FM. α7 Nicotinic acetylcholine receptor relieves angiotensin II-induced senescence in vascular smooth muscle cells by raising nicotinamide adenine dinucleotide-dependent SIRT1 activity. Arterioscler Thromb Vasc Biol 2016, 36: 1566–1576.Google Scholar
  56. 56.
    Tracey KJ. Reflexes in immunity. Cell 2016, 164: 343–344.Google Scholar
  57. 57.
    Liu Y, Wu D, Song F, Zhu C, Hui Y, Zhu Q, et al. Activation of a7 nicotinic acetylcholine receptors prevents monosodium iodoacetate-induced osteoarthritis in rats. Cell Physiol Biochem 2015, 35: 627–638.Google Scholar
  58. 58.
    de Jonge WJ, van der Zanded EP, The FO, Bijlsma MF, van Westerloo DJ, Bennink RJ, et al. Stimulation of the vagus nerve attenuates macrophage activation by activating the Jak2-STAT3 signaling pathway. Nat Immunol 2005, 6: 844–851.Google Scholar
  59. 59.
    Lu B, Kwan K, Levine YA, Olofsson PS, Yang H, Li J, et al. α7 Nicotinic Acetylcholine receptor signaling inhibits inflammasome activation by preventing mitochondrial DNA release. Molecular Medicine 2014, 20: 350–358.Google Scholar
  60. 60.
    Vida G, Peña G, Deitch EA, Ulloa L. α7cholinergic receptor mediates vagal induction of splenic norepinephrine. J Immunol 2011, 186: 4340–4346.Google Scholar
  61. 61.
    Vida G, Peña G, Kanashiro A, Thompson-Bonilla MR, Palange D, Deitch EA, et al. β2-Adrenoreceptors of regulatory lymphocytes are essential for vagal neuromodulation of the innate immune system. FASEB J 2011, 25: 4476–4485.Google Scholar
  62. 62.
    Rosasballina M, Olofsson PS, Ochani M, Valdésferrer SI, Levine YA, Reardon C, et al. Acetylcholine-synthesizing T cells relay neural signals in a vagus nerve circuit. Science 2011, 334: 98–101.Google Scholar
  63. 63.
    Reardon C. Neuro-immune interactions in the cholinergic anti-inflammatory reflex. Immunol Lett 2016, 178: 92–96.Google Scholar
  64. 64.
    Huang J, Qian J, Yao W, Wang N, Zhang Z, Cao C, et al. Vagus nerve stimulation reverses ventricular electrophysiological changes induced by hypersympathetic nerve activity. Exp Physiol 2015, 100: 239–248.Google Scholar
  65. 65.
    Wang L, Wei G, Song L, Li C, Zhang F, Yang Y, et al. Effect of renal sympathetic denervation on ventricular and neural remodeling. Herz 2018.  https://doi.org/10.1007/s00059-018-4698-y.Google Scholar
  66. 66.
    He X, Zhao M, Bi X, Sun L, Yu X, Zhao M, et al. Novel strategies and underlying protective mechanisms of modulation of vagal activity in cardiovascular diseases. Br J Pharmacol 2015, 172: 5489–5500.Google Scholar
  67. 67.
    Jope RS. High affinity choline transport and acetylCoA production in brain and their roles in the regulation of acetylcholine synthesis. Brain Res 1979, 180: 313–344.Google Scholar
  68. 68.
    Das PK, Dube SN, Rathor RS. Effect of a cholinesterase inhibitor on cardiac acetylcholine and tissue glycogen contents in anesthetized dogs. Adv Myocardiol 1980, 1: 405–416.Google Scholar
  69. 69.
    Da SV, Gnecchi-Ruscone T, Bellina V, Oliveira M, Maciel L, de Carvalho AC, et al. Acute adenosine increases cardiac vagal and reduces sympathetic efferent nerve activities in rats. Exp Physiol 2012, 97: 719–729.Google Scholar
  70. 70.
    Bi XY, He X, Zhao M, Yu XJ, Zang WJ. Role of endothelial nitric oxide synthase and vagal activity in the endothelial protection of atorvastatin in ischemia/reperfusion injury. J Cardiovasc Pharmacol 2013, 61: 391–400.Google Scholar
  71. 71.
    Xu XL, Zang WJ, Lu J, Kang XQ, Li M, Yu XJ. Effects of carvedilol on M2 receptors and cholinesterase-positive nerves in adriamycin-induced rat failing heart. Auton Neurosci 2006, 130: 6–16.Google Scholar
  72. 72.
    Maida KD, Vieira S, Gastaldi AC, Bezerra VB, De Araujo JE, de Souza HC. Amlodipine and enalapril promote distinct effects on cardiovascular autonomic control in spontaneously hypertensive rats: the role of aerobic physical training. J Hypertens 2016, 34: 2383–2392.Google Scholar
  73. 73.
    Zeisel SH. A brief history of choline. Ann Nutr Metab 2012, 61: 254–258.Google Scholar
  74. 74.
    Liu Y, Sun HL, Li DL, Wang LY, Gao Y, Wang YP, et al. Choline produces antiarrhythmic actions in animal models by cardiac M3 receptors: improvement of intracellular Ca2+ handling as a common mechanism. Can J Physiol Pharmacol 2008, 86: 860–865.Google Scholar
  75. 75.
    Wang S, Han HM, Pan ZW, Hang PZ, Sun LH, Jiang YN, et al. Choline inhibits angiotensin II-induced cardiac hypertrophy by intracellular calcium signal and p38 MAPK pathway. Naunyn Schmiedebergs Arch Pharmacol 2012, 385: 823–831.Google Scholar
  76. 76.
    Zhao Y, Wang C, Wu J, Wang Y, Zhu W, Zhang Y, et al. Choline protects against cardiac hypertrophy induced by increased after-load. Int J Biol Sci 2013, 9: 295–302.Google Scholar
  77. 77.
    Zhao J, Su Y, Zhang Y, Pan Z, Yang L, Chen X, et al. Activation of cardiac muscarinic M3 receptors induces delayed cardioprotection by preserving phosphorylated connexin43 and up-regulating cyclooxygenase-2 expression. Br J Pharmacol 2010, 159: 1217–1225.Google Scholar
  78. 78.
    Kruse AC, Kobilka BK, Gautam D, Sexton PM, Christopoulos A, Wess J. Muscarinic acetylcholine receptors: novel opportunities for drug development. Nat Rev Drug Discov 2014, 13: 549–560.Google Scholar
  79. 79.
    Liu JJ, Li DL, Zhou J, Sun L, Zhao M, Kong SS, et al. Acetylcholine prevents angiotensin II-induced oxidative stress and apoptosis in H9c2 cells. Apoptosis 2011, 16: 94–103.Google Scholar
  80. 80.
    Sun L, Zhao M, Yu XJ, Wang H, He X, Liu JK, et al. Cardioprotection by acetylcholine: A novel mechanism via mitochondrial biogenesis and function involving the PGC-1α pathway. J Cell Physiol 2013, 228: 1238–1248.Google Scholar
  81. 81.
    Zhao M, Sun L, Yu XJ, Miao Y, Liu JJ, Wang H, et al. Acetylcholine mediates AMPK-dependent autophagic cytoprotection in H9c2 cells during hypoxia/reoxygenation injury. Cell Physiol Biochem 2013, 32: 601–613.Google Scholar
  82. 82.
    Bi X, He X, Xu M, Zhao M, Yu X, Lu X, et al. Acetylcholine ameliorates endoplasmic reticulum stress in endothelial cells after hypoxia/reoxygenation via M3 AChR-AMPK signaling. Cell Cycle 2015, 14: 2461–2472.Google Scholar
  83. 83.
    Xu M, Bi XY, He X, Yu XJ, Zhao M, Zang WJ. Inhibition of the mitochondrial unfolded protein response by acetylcholine alleviated hypoxia/reoxygenation-induced apoptosis of endothelial cells. Cell Cycle 2016, 15: 1331–1343.Google Scholar
  84. 84.
    He X, Bi XY, Lu XZ, Zhao M, Yu XJ, Sun L, et al. Reduction of mitochondria-endoplasmic reticulum interactions by acetylcholine protects human umbilical vein endothelial cells from hypoxia/reoxygenation injury. Arterioscler Thromb Vasc Biol 2015, 35: 1623–1634.Google Scholar
  85. 85.
    Zhao M, Jia HH, Liu LZ, Bi XY, Xu M, Yu XJ, et al. Acetylcholine attenuated TNF-α-induced intracellular Ca2+ overload by inhibiting the formation of the NCX1-TRPC3-IP3R1 complex in human umbilical vein endothelial cells. J Mol Cell Cardiol 2017, 107: 1–12.Google Scholar
  86. 86.
    Androne AS, Hryniewicz K, Goldsmith R, Arwady A, Katz SD. Acetylcholinesterase inhibition with pyridostigmine improves heart rate recovery after maximal exercise in patients with chronic heart failure. Heart 2003, 89: 854–858.Google Scholar
  87. 87.
    Maggi L, Mantegazza R. Treatment of myasthenia gravis: focus on pyridostigmine. Clin Drug Invest 2011, 31: 691–701.Google Scholar
  88. 88.
    Souza AC, Grabeguimarães A, Souza J, Botacim WE, Almeida TM, Frézard FJ, et al. Development and characterization of multilamellar liposomes containing pyridostigmine. Pharm Dev Technol 2013, 19: 454–459.Google Scholar
  89. 89.
    Wang X, Yu X, Vaughan W, Liu M, Guan Y. Novel drug-delivery approaches to the blood-brain barrier. Neurosci Bull 2015, 31: 257–264.Google Scholar
  90. 90.
    Lataro RM, Silva CA, Jr FR, Rossi MA, Prado CM, Godinho RO, et al. Increase in parasympathetic tone by pyridostigmine prevents ventricular dysfunction during the onset of heart failure. Am J Physiol Regul Integr Comp Physiol 2013, 305: R908–R916.Google Scholar
  91. 91.
    Durand MT, Becari C, De OM, do Carmo JM, Silva CA, Prado CM, et al. Pyridostigmine restores cardiac autonomic balance after small myocardial infarction in mice. PLoS One 2014, 9: e104476.Google Scholar
  92. 92.
    Gavioli M, Lara A, Almeida PW, Lima AM, Damasceno DD, Rocha-Resende C, et al. Cholinergic signaling exerts protective effects in models of sympathetic hyperactivity-induced cardiac dysfunction. PLoS One 2014, 9: e100179.Google Scholar
  93. 93.
    Liu JJ, Huang N, Lu Y, Zhao M, Yu XJ, Yang Y, et al. Improving vagal activity ameliorates cardiac fibrosis induced by angiotensin II: in vivo and in vitro. Sci Rep 2015, 5: 17108.Google Scholar
  94. 94.
    Lu Y, Liu JJ, Bi XY, Yu XJ, Kong SS, Qin FF, Zhou J, Zang WJ. Pyridostigmine ameliorates cardiac remodeling induced by myocardial infarction via inhibition of the transforming growth factor-β1/TGF-β1-activated kinase pathway. J Cardiovasc Pharmacol 2014, 63: 412–420.Google Scholar
  95. 95.
    de La Fuente RN, Rodrigues B, Moraes-Silva IC, Souza LE, Sirvente R, Mostarda C, et al. Cholinergic stimulation with pyridostigmine improves autonomic function in infarcted rats. Clin Exp Pharmacol Physiol 2013, 40: 610–616.Google Scholar
  96. 96.
    Yu JG, Song SW, Shu H, Fan SJ, Liu AJ, Liu C, et al. Baroreflex deficiency hampers angiogenesis after myocardial infarction via acetylcholine-α7-nicotinic ACh receptor in rats. Eur Heart J 2013, 34: 2412–2420.Google Scholar
  97. 97.
    Durand MT, Becari C, De OM, do Carmo JM, Silva CA, Prado CM, et al. Pyridostigmine restores cardiac autonomic balance after small myocardial infarction in mice. PLoS One 2013, 9: e104476.Google Scholar
  98. 98.
    Feriani DJ, Souza GIH, Carrozzi NM, Mostarda C, Dourado PMM, Consolim-Colombo FM, et al. Impact of exercise training associated to pyridostigmine treatment on autonomic function and inflammatory profile after myocardial infarction in rats. Int J Cardiol 2017, 227: 757–765.Google Scholar
  99. 99.
    Lataro RM, Silva CA, Tefe-Silva C, Prado CM, Salgado HC. Acetylcholinesterase inhibition attenuates the development of hypertension and inflammation in spontaneously hypertensive rats. Am J Hypertens 2015, 28: 1201–1208.Google Scholar
  100. 100.
    Lu Y, Wu Q, Liu LZ, Yu XJ, Liu JJ, Li MX, et al. Pyridostigmine protects against cardiomyopathy associated with adipose tissue browning and improvement of vagal activity in high-fat diet rats. Biochim Biophys Acta 2018, 1864: 1037–1050.Google Scholar
  101. 101.
    Sun L, Li DL, Zhao M, He X, Yu XJ, Miao Y, et al. The role of muscarinic receptors in the beneficial effects of adenosine against myocardial reperfusion injury in rats. PLoS One 2011, 6: e25618.Google Scholar
  102. 102.
    Sun L, Lu J, Yu XJ, Li DL, Xu XL, Wang B, et al. Adenine sulfate improves cardiac function and the cardiac cholinergic system after myocardial infarction in rats. J Pharmacol Sci 2011, 115: 205–213.Google Scholar
  103. 103.
    Yves J, Fabrice J, Jean Guillaume S, Sylvie R, Stéphane D, Jocelyne C, et al. Endogenous adenosine release is involved in the control of heart rate in rats. Can J Physiol Pharmacol 2015, 93: 667–675.Google Scholar
  104. 104.
    Millar PJ, Floras JS. Statins and the autonomic nervous system. Clin Sci (Lond) 2014, 126: 401–415.Google Scholar
  105. 105.
    Vrtovec B, Okrajsek R, Golicnik A, Ferjan M, Starc V, Radovancevic B. Atorvastatin therapy increases heart rate variability, decreases QT variability, and shortens QTc interval duration in patients with advanced chronic heart failure. J Card Fail 2005, 11: 684–690.Google Scholar
  106. 106.
    Chen WR, Liu HB, Sha Y, Shi Y, Wang H, Yin DW, et al. Effects of statin on arrhythmia and heart rate variability in healthy persons with 48-hour sleep deprivation. J Am Heart Assoc 2016, 5: e003833.Google Scholar
  107. 107.
    Tsujimoto T, Kajio H. Favorable effects of statins in the treatment of heart failure with preserved ejection fraction in patients without ischemic heart disease. Int J Cardiol 2018, 255: 111–117.Google Scholar
  108. 108.
    Wallukat G. The β-Adrenergic Receptors. Herz 2002, 27: 683–690.Google Scholar
  109. 109.
    Jahns R, Boivin V, Lohse MJ. Beta 1-adrenergic receptor-directed autoimmunity as a cause of dilated cardiomyopathy in rats. Int J Cardiol 2006, 112: 7–14.Google Scholar
  110. 110.
    Malfatto G, Facchini M, Branzi G, Riva B, Sala L, Perego GB. Long-term treatment with the beta-blocker carvedilol restores autonomic tone and responsiveness in patients with moderate heart failure. J Cardiovasc Pharmacol 2003, 42: 125–131.Google Scholar
  111. 111.
    Zhan DY, Morimoto S, Du CK, Wang YY, Lu QW, Tanaka A, et al. Therapeutic effect of {beta}-adrenoceptor blockers using a mouse model of dilated cardiomyopathy with a troponin mutation. Cardiovasc Res 2009, 84: 64–71.Google Scholar
  112. 112.
    Ondocin PT, Narsipur SS. Influence of angiotensin converting enzyme inhibitor treatment on cardiac autonomic modulation in patients receiving haemodialysis. Nephrology (Carlton) 2006, 11: 497–501.Google Scholar
  113. 113.
    Thireau J, Zalvidea S, Meschin P, Pasquie JL, Aimond F, Richard S. ACE Inhibitor Delapril Prevents Ca(2+)-Dependent blunting of IK1 and ventricular arrhythmia in ischemic heart disease. Curr Mol Med 2015, 15: 642–651.Google Scholar

Copyright information

© The Author(s) 2018

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  • Longzhu Liu
    • 1
  • Ming Zhao
    • 1
  • Xiaojiang Yu
    • 1
  • Weijin Zang
    • 1
    Email author
  1. 1.Department of Pharmacology, School of Basic Medical SciencesXi’an Jiaotong University Health Science CenterXi’anChina

Personalised recommendations